BST Position Update – September 10, 2015
. . . . New Link Genetics (NASDAQ: $NLNK) – Buy up to $50.00
NLNK recently announced that their Phase 3 clinical study for VSV-ZEBOV is expected to meet its primary endpoint.
It is exciting times for the company, as the vaccine will more than likely end up in consumer hands. This of course also means major profit for them and for you.
Last week, I recommended buying the stock and it has already gone up 11% in one week!
If you haven’t yet bought NLNK, there is still time to purchase. My recommended buy up to price is $50.00 and the stock is currently trading at $48.90.
Get in on this hot biotech stock while you still can. The trials are close to completion and when this vaccine hits the market, stock prices will skyrocket.
. . . . BioLineRx (NASDAQ: $BLRX) – Buy up to $2.50
We’ve been waiting on a positive catalyst for BLRX to develop for some time.
Well, today’s the day we’ve been waiting for… the company announced that it has filed the regulatory paperwork needed to start a Phase 2 trial for BL-8040.
The trials are testing the drug as a novel treatment for two bone marrow failure conditions – hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA).
The trial is expected to commence in the next few months after they get regulatory approval.
We thought BL-8040 showed great promise when we recommended it… and we’re finally starting to see the stock gain some traction. You can buy shares of BLRX up to $2.50.
Action To Take
- Buy NLNK
- Buy BLRX
Category: BST Update
